Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$10.18
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
Entrada Therapeutics Analyst Ratings and Price Targets | NASDAQ:TRDA | Benzinga
Entrada Therapeutics Inc has a consensus price target of $23.4 based on the ratings of 5 analysts. The high is $29 issued by Roth MKM on December 5, 2024. The low is $18 issued by Goldman Sachs on November 8, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Roth MKM on February 25, 2025, February 4, 2025, and December 5, 2024, respectively. With an average price target of $23 between HC Wainwright & Co., HC Wainwright & Co., and Roth MKM, there's an implied 126.04% upside for Entrada Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Roth MKM
Oppenheimer
Oppenheimer
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Entrada Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/25/2025 | Buy Now | 96.56% | HC Wainwright & Co. | Raghuram Selvaraju43% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 02/04/2025 | Buy Now | 96.56% | HC Wainwright & Co. | Raghuram Selvaraju43% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2024 | Buy Now | 185.01% | Roth MKM | Boobalan Pachaiyappan69% | → $29 | Initiates | → Buy | Get Alert |
| 11/06/2024 | Buy Now | 175.18% | Oppenheimer | Francois Brisebois44% | $25 → $28 | Maintains | Outperform | Get Alert |
| 11/06/2024 | Buy Now | 96.56% | HC Wainwright & Co. | Raghuram Selvaraju43% | $18 → $20 | Maintains | Buy | Get Alert |
| 08/26/2024 | Buy Now | 145.7% | Oppenheimer | Francois Brisebois44% | $25 → $25 | Reiterates | Outperform → Outperform | Get Alert |
| 08/14/2024 | Buy Now | 76.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 06/25/2024 | Buy Now | 76.9% | HC Wainwright & Co. | Raghuram Selvaraju43% | $20 → $18 | Maintains | Buy | Get Alert |
| 03/18/2024 | Buy Now | 96.56% | HC Wainwright & Co. | Raghuram Selvaraju43% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
| 01/05/2024 | Buy Now | 116.22% | Oppenheimer | Hartaj Singh47% | → $22 | Initiates | → Outperform | Get Alert |
| 11/27/2023 | Buy Now | 96.56% | HC Wainwright & Co. | Raghuram Selvaraju43% | $25 → $20 | Maintains | Buy | Get Alert |
| 09/22/2023 | Buy Now | 145.7% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 145.7% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 145.7% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2023 | Buy Now | 145.7% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2023 | Buy Now | 145.7% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $25 | Initiates | → Buy | Get Alert |
| 11/08/2022 | Buy Now | 76.9% | Goldman Sachs | Chris Shibutani54% | $13 → $18 | Maintains | Neutral | Get Alert |
| 08/16/2022 | Buy Now | 27.76% | Goldman Sachs | Chris Shibutani54% | $10 → $13 | Maintains | Neutral | Get Alert |
| 05/24/2022 | Buy Now | -1.72% | Goldman Sachs | Chris Shibutani54% | $22 → $10 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Entrada Therapeutics (TRDA) stock?
The latest price target for Entrada Therapeutics (NASDAQ:TRDA) was reported by HC Wainwright & Co. on February 25, 2025. The analyst firm set a price target for $20.00 expecting TRDA to rise to within 12 months (a possible 96.56% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Entrada Therapeutics (TRDA)?
The latest analyst rating for Entrada Therapeutics (NASDAQ:TRDA) was provided by HC Wainwright & Co., and Entrada Therapeutics reiterated their buy rating.
When was the last upgrade for Entrada Therapeutics (TRDA)?
There is no last upgrade for Entrada Therapeutics
When was the last downgrade for Entrada Therapeutics (TRDA)?
There is no last downgrade for Entrada Therapeutics.
When is the next analyst rating going to be posted or updated for Entrada Therapeutics (TRDA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entrada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entrada Therapeutics was filed on February 25, 2025 so you should expect the next rating to be made available sometime around February 25, 2026.
Is the Analyst Rating Entrada Therapeutics (TRDA) correct?
While ratings are subjective and will change, the latest Entrada Therapeutics (TRDA) rating was a reiterated with a price target of $20.00 to $20.00. The current price Entrada Therapeutics (TRDA) is trading at is $10.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.